Shots:

• Tavros to receive $17.5M up front, ~$430.5M upon achievement of prespecified preclinical, clinical development & commercial milestones along with royalties. Vividion will get the rights to opt-in ~5 additional targets with ~$482M in additional fees
• The collaboration enables Tavros to use its functional & computational genomics technologies to identify vulnerabilities in cancers, new targets & biomarkers, and develop novel clinical methods for existing molecules. The collaboration combines 2 orthogonal, highly novel & complementary approaches to drug discovery
• Tavros increases the actionability of the platform into a new target space by combining the precision oncology platform with Vividion's unmatched ability to drug the traditionally undruggable

Ref: Businesswire | Image: Tavros Therapeutics